My thought; the authorized share increase wouldn't
Post# of 30025
Posted On: 08/08/2014 7:04:36 PM
My thought; the authorized share increase wouldn't be necessary, but is a more attractive share structure if they did something like this :
Split the company into its respective divisions (therapeutics and diagnostics), each of which would have 1b shares authorized. Then the current OS gets split in half between the divisions (~375m shares each). You, as a shareholder, would receive shares in both companies. Half your shares go to the diagnostics and half goes to the therapeutics side.
There would then be two companies, both with ~375m / 1b shares outstanding.
I see this as a way to reward shareholders for LymPro due to the minimal and/or no dilution necessary to further develop and commercialize it before revenues start coming in. The therapeutics side would likely be more diluted over the years to fund MANF's numerous indications. Every indication, study, clinical trial, etc. will need to be paid for somehow, and although JV's, partners, grants, etc are all very real possibilities, so is the concept of dilution to fund r&d.
This offers investors a nice choice, the diagnostics side with revenues coming in shortly, and the therapeutics side with enormous upside potential (MANF), albeit a bit farther out.
Just my thoughts.
Split the company into its respective divisions (therapeutics and diagnostics), each of which would have 1b shares authorized. Then the current OS gets split in half between the divisions (~375m shares each). You, as a shareholder, would receive shares in both companies. Half your shares go to the diagnostics and half goes to the therapeutics side.
There would then be two companies, both with ~375m / 1b shares outstanding.
I see this as a way to reward shareholders for LymPro due to the minimal and/or no dilution necessary to further develop and commercialize it before revenues start coming in. The therapeutics side would likely be more diluted over the years to fund MANF's numerous indications. Every indication, study, clinical trial, etc. will need to be paid for somehow, and although JV's, partners, grants, etc are all very real possibilities, so is the concept of dilution to fund r&d.
This offers investors a nice choice, the diagnostics side with revenues coming in shortly, and the therapeutics side with enormous upside potential (MANF), albeit a bit farther out.
Just my thoughts.
(0)
(0)